Investigators observe low rates of treatment discontinuation and adverse effects with radium-223 as treatment for castration-resistant prostate cancer and bone metastases.
Miranda Lankas
Advertisement
Articles by Miranda Lankas
Darolutamide produces a lower rate of discontinuation compared with enzalutamide or apalutamide among patients with non-metastatic, castration-resistant prostate cancer.
Treatment with ibermodide on its own or with anti-CD20 antibodies was well tolerated and demonstrated encouraging responses among patients with relapsed or refractory lymphoma.
Pre- and postmenopausal women with breast cancer may experience cognitive impairment with chemotherapy and endocrine therapy, which may return to baseline after 36 months.
Antitumor activity and safety of pembrolizumab plus abiraterone acetate appears to be sustained in chemotherapy-naïve castration-resistant prostate cancer.
Advertisement
Latest Updated Articles
Chemotherapy Plus Endocrine Therapy May Confer Further Cognitive Impairment vs. Endocrine Therapy Alone for Breast Cancer Regardless of Menopausal StatusPublished: December 7th 2022 | Updated:
Ra-223 Improves Outcomes in Prostate Cancer With Bone MetastasesPublished: February 18th 2023 | Updated:
Advertisement
Advertisement
Trending on CancerNetwork
1
Cancer Vaccine/Pembrolizumab Improves PFS in Treatment-Naive Melanoma
2
Relacorilant Regimen Improves PFS in Platinum-Resistant Ovarian Cancer
3
Sacituzumab Tirumotecan Improves Survival in Second-Line EGFR+ NSCLC
4
How Can Cellular Therapies Become More Affordable Across the World?
5
